Literature DB >> 6154064

Post-transfusion survival of hydroxyethyl starch 450/0.70 in man: a long-term study.

J M Mishler, C R Ricketts, E J Parkhouse.   

Abstract

Intravascular persistence concomitant with changes occurring in the circulating molecular size distribution were determined in five healthy normovolaemic men dosed with 7 ml/kg of a 6% (w/v) solution of a species of hydroxyethyl starch (HES 450/0.70) possessing a M(w)- of 450 000 daltons combined with a molar hydroxyethyl group substitution (MS) of 0.70 (70 hydroxyethyl groups/100 glucose residues). The concentration of HES 450/0.70 in serum fell to 24% of its peak value (measured 2 minutes post injection) one week after the infusion. By 17 weeks after injection, < 1.0% remained in the intravascular space. The HES 450/0.70 material recovered from the bloodstream 2 minutes after injection was shown by gel filtration on a column of Sepharose CL-4B to be less polydisperse than the injected solution. The K(av) calculated for the peak of material eluted after one week showed a definite shift of molecular size toward that of a lower molecular weight composition. However, at four weeks the value of K(av) indicated a shift toward the high molecular weight region of the injected solution, and by seven weeks this movement was quite pronounced. These data clearly indicate the complex nature of the removal of HES 450/0.70 from the intravascular space of man and appear to substantiate previous clinical studies reporting that the MS plays the major role influencing the rate of elimination of this material from the bloodstream.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6154064      PMCID: PMC1146011          DOI: 10.1136/jcp.33.2.155

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  13 in total

1.  Clinical trial of 6 per cent hydroxyethyl starch (a new plasma expander).

Authors:  T F Solanke
Journal:  Br Med J       Date:  1968-09-28

2.  A clinical physiologic study of hydroxyethyl starch.

Authors:  W Metcalf; A Papadopoulos; R Tufaro; A Barth
Journal:  Surg Gynecol Obstet       Date:  1970-08

3.  Hydroxyethyl starch: an agent for hypovolemic shock treatment.

Authors:  J M Mishler; H Borberg; P M Emerson; R Gross
Journal:  J Surg Res       Date:  1977-10       Impact factor: 2.192

Review 4.  Hydroxyethyl starch as an experimental adjunct to leukocyte separation by centrifugal means: review of safety and efficacy.

Authors:  J M Mishler
Journal:  Transfusion       Date:  1975 Sep-Oct       Impact factor: 3.157

5.  Changes in the molecular composition of circulating hydroxyethyl starch.

Authors:  S P Farrow; M Hall; C R Ricketts
Journal:  Br J Pharmacol       Date:  1970-04       Impact factor: 8.739

6.  Freeze preservation of platelets using hydroxyethyl starch (HES); a preliminary report.

Authors:  C Choudhury
Journal:  Cryobiology       Date:  1978-10       Impact factor: 2.487

7.  Changes in the molecular composition of circulating hydroxyethyl starch following consecutive daily infusions in man.

Authors:  J M Mishler; C R Ricketts; E J Parkhouse
Journal:  Br J Clin Pharmacol       Date:  1979-05       Impact factor: 4.335

8.  A clinical study of low molecular weight-hydroxyethyl starch, a new plasma expander.

Authors:  J M Mishler; E S Parry; B A Sutherland; J R Bushrod
Journal:  Br J Clin Pharmacol       Date:  1979-06       Impact factor: 4.335

9.  [Mathematical decription of the human intravascular elimination of HAS after repeated infusions].

Authors:  J M Mishler; M Beez
Journal:  Infusionsther Klin Ernahr       Date:  1979-04

10.  Intravascular persistence of hydroxyethyl starch in man.

Authors:  J C Boon; F Jesch; J Ring; K Messmer
Journal:  Eur Surg Res       Date:  1976       Impact factor: 1.745

View more
  3 in total

1.  Urinary excretion kinetics of hydroxyethyl starch 350/0.60 in normovolaemic man.

Authors:  J M Mishler; C R Ricketts; E J Parkhouse
Journal:  J Clin Pathol       Date:  1981-04       Impact factor: 3.411

2.  Changes in the molecular size distribution and post-transfusion survival of hydroxyethyl starch 350/0.60 as influenced by a lower degree of hydroxyethylation: a study in normal man.

Authors:  J M Mishler; C R Ricketts; E J Parkhouse
Journal:  J Clin Pathol       Date:  1980-09       Impact factor: 3.411

Review 3.  Clinical pharmacokinetic considerations in the use of plasma expanders.

Authors:  U Klotz; H Kroemer
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.